- Home
- GORV vs ELEV Comparison
GORV vs ELEV Comparison
Compare GORV & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- ELEV
- Stock Information
- Founded
- GORV 1976
- ELEV 2019
- Country
- GORV United States
- ELEV United States
- Employees
- GORV N/A
- ELEV N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- ELEV Health Care
- Exchange
- GORV Nasdaq
- ELEV Nasdaq
- Market Cap
- GORV 25.3M
- ELEV 22.6M
- IPO Year
- GORV 2015
- ELEV 2021
- Fundamental
- Price
- GORV $7.14
- ELEV $0.38
- Analyst Decision
- GORV Hold
- ELEV Hold
- Analyst Count
- GORV 2
- ELEV 6
- Target Price
- GORV $2.00
- ELEV $1.77
- AVG Volume (30 Days)
- GORV 80.2K
- ELEV 947.0K
- Earning Date
- GORV 08-15-2025
- ELEV 08-05-2025
- Dividend Yield
- GORV N/A
- ELEV N/A
- EPS Growth
- GORV N/A
- ELEV N/A
- EPS
- GORV N/A
- ELEV N/A
- Revenue
- GORV $767,257,000.00
- ELEV N/A
- Revenue This Year
- GORV $15.65
- ELEV N/A
- Revenue Next Year
- GORV $20.54
- ELEV N/A
- P/E Ratio
- GORV N/A
- ELEV N/A
- Revenue Growth
- GORV N/A
- ELEV N/A
- 52 Week Low
- GORV $3.95
- ELEV $0.22
- 52 Week High
- GORV $106.80
- ELEV $3.28
- Technical
- Relative Strength Index (RSI)
- GORV 51.39
- ELEV 55.29
- Support Level
- GORV $6.49
- ELEV $0.36
- Resistance Level
- GORV $8.01
- ELEV $0.38
- Average True Range (ATR)
- GORV 0.74
- ELEV 0.01
- MACD
- GORV 0.04
- ELEV -0.00
- Stochastic Oscillator
- GORV 61.32
- ELEV 59.64
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.